Teva gets taste of its own antidepressant
Executive Summary
At least seven of the 16 firms with approvals for generic sertraline hydrochloride decide to launch their versions of Pfizer's antidepressant Zoloft after Teva's 180-day exclusivity expired Feb. 6. In January, Teva filed patent infringement lawsuits against multiple generic manufacturers, claiming the generics violate patents which relate to methods for manufacturing. According to IMS data, the generic substitution rate for Zoloft was 89 percent as of Dec. 15, with Teva controlling 45.4 percent of the generic share. The remaining portion went to Greenstone, Pfizer's authorized generics business...
You may also be interested in...
Boehringer Ingelheim, Gubra Enter Third Obesity Deal
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
What’s Next? Five Things To Look Out For In March
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: